| Bioactivity | DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is utilized for diagnosis and therapy of cancer, through combination with radioactive elements[1]. |
| CAS | 209277-09-8 |
| Sequence | DOTA-{d-Phe}-Cys-Phe-{d-Trp}-Lys-Thr-Cys-{d-Threoninol} (Disulfide bridge: Cys2-Cys7) |
| Shortening | DOTA-{d-Phe}-CF-{d-Trp}-KTC-{d-Threoninol} (Disulfide bridge: Cys2-Cys7) |
| Formula | C65H92N14O17S2 |
| Molar Mass | 1405.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bodei L, et al., Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46. |
DOTA-Octreotide
CAS: 209277-09-8 F: C65H92N14O17S2 W: 1405.64
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is utilized for diagnosis and th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.